Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05695261
Other study ID # P00043954
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 8, 2023
Est. completion date March 1, 2027

Study information

Verified date October 2023
Source Boston Children's Hospital
Contact Angela Zhang
Phone 617-919-1566
Email Angela.Zhang@childrens.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase II randomized double-blind placebo-controlled trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients. In this research the investigators would like to learn more about ways to treat peanut allergies. The primary objective is to evaluate whether MTT with antibiotic pretreatment can increase the threshold of peanut reactivity during a double-blind placebo-controlled food challenge from <=100 mg peanut protein to 300 mg after 28 days of MTT /placebo therapy and 4 months post therapy initiation.


Description:

This is a phase II randomized double-blind placebo-controlled trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in 24 peanut allergic patients, 12-17 years of age. After reacting to <=100 mg peanut protein during initial DBPCFC, patients will be randomized to receive either oral Vancomycin and Neomycin or placebo/placebo for 7 days. Patients will then come to the Experimental and Therapeutic Unit (ETU) to receive orally 5 capsules of MTT or placebo under medical supervision. Patients will then take 2 capsules of MTT or placebo daily for 27 days. Patients will return to the ETU to undergo a second DBPCFC within 2 weeks of end of MTT/placebo treatment and 4 months post MTT initiation. They will return to the ETU for an exit visit 6 months after end of treatment. Gut microbiota will be analyzed serially using state-of-the-art 16SRNA sequencing prior to transplantation, then at 4 weeks, 4-month, and 6 months post transplantation. Immunological biomarkers and mechanistic studies will be performed on blood taken at baseline, second DBPCFC visit and exit visit. Adverse events will be monitored carefully throughout the study.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date March 1, 2027
Est. primary completion date January 11, 2027
Accepts healthy volunteers No
Gender All
Age group 12 Years to 17 Years
Eligibility Inclusion Criteria: 1. Develop dose limiting symptoms to peanut during a DPBCFC conducted in accordance with PRACTALL (Practical Issues in Allergology, Joint United States/European Union Initiative) guidelines at 1 mg, 3 mg, 10 mg, 30 mg, or 100 mg peanut protein. 2. Has a positive SPT to peanut (=3mm) and/or a positive peanut-specific IgE >0.35kU/L. 3. For asthmatic patients, has a Spirometry or Peak Flow with Measurement of FEV1>=80% of predicted 4. Has a negative urine hCG test if a female participant. 5. Agrees to use an acceptable single-barrier form of birth control from enrollment through the exit DBPCFC study visit if female of childbearing potential and sexually active. An example of a single-barrier method of contraception includes condoms or oral contraceptives. Acceptable methods of birth control include implants, injectables, combined oral contraceptives, some intrauterine contraceptive devises (IUDs), sexual abstinence, a vasectomized partner, the contraceptive patch, the contraceptive ring, and condoms. 6. Able to swallow 2 empty capsules size 00. 7. Able to give informed assent and guardian willing to give informed consent. 8. Willing and able to participate in the study requirements, including study visits, DBPCFCs, serial stool collection 9. Willing to undergo telephone or email follow-up to assess for safety and adverse events. Exclusion Criteria: 1. Patients with a history of severe anaphylaxis to any food (hypotension requiring vasopressor support, hypoxia requiring mechanical ventilation, or neurological compromise) 2. Patients with a history of IgE mediated reactions to food (excluding allergic reactions to peanut, tree nuts, egg and milk, provided that MTT does not contain traces of these l food estimated to be above the LOAEL in 5 capsules combined, and excluding oral allergy syndrome). 3. Patients with chronic illness other than controlled asthma that is mild intermittent, mild- persistent or moderate persistent, mild eczema and allergic rhinitis. Exceptions can be made per PI discretion if illness is not expected to affect allergies or treatment. 4. Recurrent or chronic infections necessitating frequent systemic (including oral) antibiotic administration. 5. Patients on chronic systemic immunosuppressive therapies. 6. Patients who are diagnosed with active, chronic urticaria. 7. Patients who have received peanut oral immunotherapy within the past 6 months. 8. Patients who are on the up-dosing phase of aeroallergen immunotherapy or patients who have received Omalizumab or dupilumab therapy within the past 6 months. 9. Women who are pregnant or breast feeding or planning to get pregnant during the time of the study. 10. Sexually active female patients who refuse to use contraception from enrollment through the third DBPCFC study visit 11. Patient with GI conditions including inflammatory bowel disease, eosinophilic esophagitis, food protein induced enterocolitis, uncontrolled reflux despite medication, uncontrolled chronic constipation despite medication, esophageal dysmotility, swallowing dysfunction, delayed gastric emptying syndromes, pill esophagitis or history of aspiration pneumonia within 3 months prior to screening. 12. Patient with current rheumatologic conditions. Exceptions can be made per PI discretion if illness is not expected to affect allergies or treatment. 13. Patients with neutropenia <1000 unit of measure? 14. Patients participating or planning to participate in the next 6 months in interventional research trials. Exceptions can be made per PI discretion. 15. Patients who have received systemic corticosteroids therapy for 1 week or more over the past 2 months. 16. Patient with an allergy to Vancomycin or Neomycin

Study Design


Intervention

Biological:
Microbial Transplantation Therapy
Subjects randomized to the MTT/antibiotic arm will be administered oral MTT capsules over the course of 28 days.
Drug:
Antibiotic
Subjects randomized to the MTT/antibiotic arm will receive oral antibiotics for 7 days prior to the MTT administration visit.
Other:
Placebo (in place of MTT)
Subjects randomized to the placebo arm will be administered oral placebo capsules in place of MTT over the course of 28 days.
Placebo (in place of antibiotics)
Subjects randomized to the placebo arm will receive oral placebo in place of antibiotics for 7 days prior to the MTT administration visit.

Locations

Country Name City State
United States Boston Children's Hospital Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Rima Rachid University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in threshold of peanut reactivity during DBPCFC (<=100 mg to 300 mg peanut protein) Changes in threshold of peanut reactivity during DBPCFC after 28 days of MTT from <=100 mg to 300 mg peanut protein and 4 months post therapy initiation. 4 months post MTT
Secondary Changes in threshold of peanut reactivity during DBPCFC (<=100 mg to 600 mg peanut protein) Changes in threshold of peanut reactivity during DBPCFC after 28 days of MTT from <=100 mg to 600 mg peanut protein and 4 months post therapy initiation. 4 months post MTT
Secondary Adverse Events MTT Treatment emergent adverse events 8 months
Secondary Changes in Skin Test Wheal Size and IgE level Changes in skin test peanut specific wheal size, peanut-specific IgE level over time 8 months
Secondary Changes in Gut Microbial Composition Changes in gut microbial composition and persistence of that change over time 8 months
Secondary Changes in Biomarkers Changes in biomarkers including RoRgt+Treg cells and Th2 helper cells frequencies after MTT therapy 8 months
See also
  Status Clinical Trial Phase
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05839405 - Food Allergy in the Brain
Completed NCT02552537 - iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions Phase 4
Completed NCT01634737 - Crustacean Allergy and Dust Mites Sensitization N/A
Recruiting NCT05521711 - TRADE Trial - Tree Nut Immunotherapy Route Development and Evaluation N/A
Completed NCT05072665 - Fast Allergy Sensitivity Test N/A
Active, not recruiting NCT04887441 - Allergology: Information, Data and Knowledge Organization
Recruiting NCT03265262 - The Basophil Activation Test as a Diagnostic Tool in Pediatric Food Allergy N/A
Completed NCT04186949 - Early Origins of Allergy and Asthma
Completed NCT02490007 - Pertussis Immunisation and Food Allergy
Recruiting NCT03151252 - Improvement of Foodallergy Diagnostic in Gastrointestinal Tract N/A
Completed NCT02159833 - Intranasal Diagnostics in Food Allergy: a Feasibility Study N/A
Completed NCT02354729 - Encouraging Allergic Young Adults to Carry Epinephrine N/A
Completed NCT02377284 - Prevention and Management of Food Allergies N/A
Completed NCT02640560 - One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish N/A
Enrolling by invitation NCT06097572 - Improved Diagnostics in Food Allergy Study N/A
Recruiting NCT04606615 - Skin Barrier Abnormalities and Oxidative Stress Response
Recruiting NCT05785299 - Clinical Versus Home Introduction of Milk in Children With Non-IgE-mediated Cow's Milk Allergy N/A
Not yet recruiting NCT06112873 - Quality of Life in Food Allergy: Validation of Three Mini-questionnaires
Completed NCT03337802 - Effect of Mediterranean Diet During Pregnancy on the Onset of Overweight and Obesity in the Offspring N/A